In , Park Medi World Ltd (Hospitals/Medical Services) is outperforming Nifty 500 with +64.4% relative strength. Fundamentals: Weak. On a 8-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Earnings deceleration risks from management commentary
Trigger: Each new hospital starts with high fixed costs (doctors, staff, facilities) and low revenue until occupancy ramps. At 30% EBITDA margin breakeven, sub-30% occupancy is loss-making at the hospital unit level. With 660 beds added simultaneously, total integration burden is elevated.
Monitor: logistics
Trigger: Government scheme dependency creates twin risks: payment delays (working capital strain) and rate risk (if schemes revise coverage or cut rates). For Park, with 4.5 months receivables on ₹1,800+ Cr revenue, that's ~₹675 Cr of capital tied up at any time — at a zero-debt company, this is the primary balance sheet stress.
Monitor: regulatory
Trigger: Scaling from 3,250 to 5,260 beds requires hiring ~500+ additional full-time doctors over 2 years — a significant challenge in India's specialist physician market, particularly for quaternary care specialties like cardiac surgery and neurosurgery
Monitor: labor
Trigger: Medical consumables, disposables, and drugs are variable costs that scale with patient volumes. With 24% EBITDA margin and 18% material intensity, a significant consumables cost spike would directly compress margins
Monitor: commodity
Key quotes from recent conference calls
“Adding 660 beds in Q4 FY26 (Agra & Panchkula). Agra currently at 30% occupancy on 180 beds; Park will operationalize all 360 beds with full super-specialty services — CFO Rajesh Sharma Q3 concall. Delays in ramping up occupancy to the 30% EBITDA breakeven mark could pressure short-term margins. [Risk (logistics): MEDIUM]”
“High dependency on government payers (83%) leads to a receivable cycle of 4.5 months. Management is attempting to reduce to 3.5-4 months through faceless portal improvements. Disallowed claims at 8-9% (below industry average) — Q3 FY26 concall [Risk (regulatory): MEDIUM]”
“Full-Time Doctor Model: Employs 1,200 full-time doctors with no visiting consultants. Industry-low consultant attrition rate of 18.9%. Clinical staff rewarded based on patient satisfaction and outcomes rather than revenue volume — Q3 FY26 concall [Risk (labor): LOW]”
“Cost of material consumed/services rendered: ₹758 Mn in Q3 FY26 vs ₹721 Mn in Q3 FY25 — consumables cost growing at ~5% YoY vs revenue growth of 18% [Risk (commodity): LOW]”
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +18% | +9% | Insufficient Data |
| PAT (Net Profit) | +15% | +2% | Insufficient Data |
| OPM | 24.0% | 0 bps | Insufficient Data |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Park Medi World Ltd's latest quarterly results (Dec 2025) show
Park Medi World Ltd's profit is growing with an insufficient_data trend.
Park Medi World Ltd's revenue growth trend is insufficient_data.
Park Medi World Ltd's operating margin is insufficient_data.
Park Medi World Ltd's long-term compounding rates
Park Medi World Ltd's earnings growth is insufficient_data with insufficient_data on a sequential basis.
Park Medi World Ltd appears significantly overvalued based on our fair value analysis.
Park Medi World Ltd's current PE ratio is 51.0x.
Park Medi World Ltd's current PE is 51.0x.
Park Medi World Ltd is rated Weak with a fundamental score of 32.67/100. This score is calculated from objective financial metrics
Park Medi World Ltd has a debt-to-equity ratio of N/A.
Park Medi World Ltd's return ratios over recent years
Park Medi World Ltd's operating cash flow is positive (FY2025).
Park Medi World Ltd currently does not pay a significant dividend (yield 0.00%).
Park Medi World Ltd's shareholding pattern (Mar 2026)
Park Medi World Ltd's promoter holding has remained stable recently.
Park Medi World Ltd has been outperforming Nifty 500 for 8 consecutive weeks, indicating consistent outperformance.
Park Medi World Ltd is an established outperformer with 8 weeks of consecutive Nifty 500 outperformance.
Park Medi World Ltd has 4 key risks worth monitoring
In Q3 FY26, Park Medi World Ltd's management highlighted
Based on quantitative research signals, here is why Park Medi World Ltd may be worth studying
Park Medi World Ltd investment thesis summary:
Park Medi World Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
